Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Solid Cancer × Clear all

Phase

Status

Recruiting 6 Completed 2 Unknown 1 Terminated 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 949 Neoplasms 837 Carcinoma, Non-Small-Cell Lung 739 Prostatic Neoplasms 505 Neoplasm Metastasis 440 Leukemia, Myeloid, Acute 440 Lung Neoplasms 405 Melanoma 396 Multiple Myeloma 394 Colorectal Neoplasms 394 Pancreatic Neoplasms 326 Lymphoma 311 Recurrence 303 Ovarian Neoplasms 302 Lymphoma, Non-Hodgkin 292 Leukemia 291 Leukemia, Lymphocytic, Chronic, B-Cell 272 Precursor Cell Lymphoblastic Leukemia-Lymphoma 249 Brain Neoplasms 233 Head and Neck Neoplasms 224 Carcinoma, Renal Cell 224 Carcinoma, Hepatocellular 218 Myelodysplastic Syndromes 206 Lymphoma, Large B-Cell, Diffuse 204 Glioblastoma 203 Lymphoma, Follicular 199 Squamous Cell Carcinoma of Head and Neck 191 Colonic Neoplasms 168 Stomach Neoplasms 157 Rectal Neoplasms 155

Interventions

pembrolizumab 1 durvalumab 1 atezolizumab 1 S-Adenosylmethionine 1 Nivolumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡